retatrutide updates FDA Approval Status 2026: Everything We Know So Far Lilly, with new data, to

The highlighted areas depict the time intervals for determining the baseline weight (W0) and final weight (mW1), defined as the median of body weight measurements in the given time interval

45 Remarkably, the recent SELECT trial proved the cardiovascular efficacy of subcutaneous semaglutide in reducing the primary cardiovascular composite endpoint (death from cardiovascular causes, non-fatal MI or non-fatal stroke) in both overweight and obese patients with established atherosclerotic CVD

JAMA (2019) 321(15):14578

Retatrutide adds glucagon-receptor agonism on top, which matters for reasons that the TRIUMPH-4 dataset has now made concrete

Small Lumps or Firmness Some people notice small lumps, called nodules, or a thickening of the skin around the area where they inject their GLP-1